Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus†
Article first published online: 22 APR 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 53, Issue 5, pages 1742–1751, May 2011
How to Cite
Pawlotsky, J.-M. (2011), Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology, 53: 1742–1751. doi: 10.1002/hep.24262
Potential conflict of interest: The author has received research grants from Gilead and Roche. He has served as an advisor for Abbott, Anadys, Biotica, Boehringer-Ingelheim, Bristol-Myers Squibb, DebioPharm, Gilead, GlaxoSmithKline, Idenix, Janssen-Cilag, Madaus-Rottapharm, Merck, Novartis, Pfizer, Pharmasset, Roche, Schering-Plough, Tibotec, Vertex, and Virco.
- Issue published online: 22 APR 2011
- Article first published online: 22 APR 2011
- Accepted manuscript online: 3 MAR 2011 08:58AM EST
- Manuscript Accepted: 11 FEB 2011
- Manuscript Received: 24 DEC 2010
The reference list is provided as online supporting material.